(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
The Nasdaq Stock Market LLC |
Director Name | Votes For | Votes Withheld | Broker Non-Votes | |||||||||||||||||
Bhaskar Chaudhuri, Ph.D. | 21,766,101 | 2,941,857 | 7,270,980 | |||||||||||||||||
William J. Link, Ph.D. | 20,817,032 | 3,890,926 | 7,270,980 |
Votes For | Votes Against | Abstain | ||||||||||||
31,896,705 | 24,949 | 57,284 |
TARSUS PHARMACEUTICALS, INC. | |||||||||||||||||||||||
Date: | June 18, 2024 | /s/ Bryan Wahl | |||||||||||||||||||||
Bryan Wahl | |||||||||||||||||||||||
General Counsel and Secretary |
Cover |
Jun. 13, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Jun. 13, 2024 |
Entity Registrant Name | TARSUS PHARMACEUTICALS, INC. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-39614 |
Entity Tax Identification Number | 81-4717861 |
Entity Address, Address Line One | 15440 Laguna Canyon Road, Suite 160 |
Entity Address, City or Town | Irvine |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92618 |
City Area Code | 949 |
Local Phone Number | 418-1801 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.0001 par value per share |
Trading Symbol | TARS |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | true |
Entity Central Index Key | 0001819790 |
Amendment Flag | false |
Security Exchange Name | NASDAQ |
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end
=?,\4L,DG[N#G 6>"*)K8
M2AEO=7Y+ [[X\%GR57KT,<#C.\DG$%81? 23>8;KT8R*AE*UV#8CTUG3-6E)
M/B>3%%+K3D":H5*8$\@"B&TDNX@.WV0Q_XWH/3X3R_N(>]J0H5EOE,KCX/B!
M.\&P81K&_^54O[,3.:8@$'V!'(O^C@99&@H)UJC+;[V@R 2,$M.^RI$/?
M%T"X9ONN2\>2-9(_CA.EBXR'IAXZ'E%Q"\3U_2#P1PVD#7:W@-O4C2=1\T7-
MCV3K1D1Z %3C)SW*Q#4V'Y^WI-KQNKFPS=5-\7U'@B:8P1*XZ#G'H&5H+0
MG.:*N87%QN1#3^+X(8+Q,U!X/*8.[LP-@Y@P1C)!0:U\%98>]@7!!U%'
MR?]B#;,"LZB/#]%2JS".8DZ\=--"F+]<=F[:'TGOIGG3[J7%8X-@O 6UO7;K
M2[=STVGW2//R(VG_WOJU>?FY35I7%Q>=7J]S=?F&2S S+>$KE4.0F\#W\N2C
MWM+!%RN7ZF](MK5 =FF1;+,,9/\[_6\MO?LJYY^NNAW/!U]^HMN%U@NSCV23@7VO&M96=K
M6\8KL348DPV\\-$OH/)#\J+S7VD1]RJ(I%+4[_13U$K1@M0,U.'4.(&UA&H:
MV.[%OFM_M1)"$XF'O'!P? 7VV'@ 9:;&Y3O?)^0E]&-K))2YAQJV)?J?\Z_)
M\M3\#07J$Q.WQ!MSCE@Y#2Z%^>X'R-IN%Y]?_ZPX3UN@5_):)52,,]=ML7L2
MA/>_!XP15L79@1BY:5]B!!O>:
M$8V)
SI/ YD->^%]O-L;'I1&9LUYSL#HD73*7@71&0V:P8MX%&:P8@9%O%GL!
MP:<.Q!L5G$3TK_3VW"6M\I#?%QP/$_'8$,40 LH< 895$@.Y5%\A)[4E*F3,
MC8#"*^9[<9%-G8LQM)T$)*?.I1#4#Q^I7/-X2;4DAJ>$F3N%VMMC2IFT%R L
M95IXYR@-(P#R@NE><(BIPS%4TRF!<9:^?HQ7U6VY9$1RPB6!E">G8LID'J0Q
M%+AU7)" /$%J/"R^&>X%A?Q!H'BCGE-"HLN+/L;+6'W)2^O3C9%Z3Y/C@OLV
MAT[%E71:@\%8